Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 287

Sort by

Sort Order Select

Journal Articles

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 565.

https://doi.org/10.1182/blood-2025-565

Published: 2025

Journal Articles

Belantamab mafodotin, nirogacestat, and pomalidomide in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4060.

https://doi.org/10.1182/blood-2025-4060

Published: 2025

Journal Articles

Phase II trial of maintenance therapy with iberdomide after autologous hematopoietic cell transplant for patients with multiple myeloma previously treated with lenalidomide

Blood (2025) 146 (Supplement 1): 4048.

https://doi.org/10.1182/blood-2025-4048

Published: 2025

Journal Articles

Effectiveness of remote patient monitoring in enabling outpatient step-up dosing for bispecifics at a large academic cancer center in the USA

Blood (2025) 146 (Supplement 1): 2751.

https://doi.org/10.1182/blood-2025-2751

Published: 2025

Journal Articles

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

William Johnson, Joseph Rocco, Rikita Patel, Adrianna Herskovits, Elena Mead, Jae Park, Alison Moskowitz, Zachary Epstein-Peterson, Robert Stuver, Neil Bapodra, Rabeya Molla, Andrew Intlekofer, Jennifer Lue, Lia Palomba, Ariela Noy, Jasmine Zain, Colette Owens, Lynnette Henshaw, Paola Ghione, Efrat Luttwak, Pallawi Torka, Andrew Zelenetz, Philip Caron, Anita Kumar, Lorenzo Falchi, Natasha Galasso, Paul Hamlin, Alexander Boardman, Kevin David, Raphael Steiner, Nivetha Ganesan, Tiffany Chang, Zainab Shahid, Wenbin Xiao, Annamaria Ballweg, Alina Markova, Mark Geyer, Lauren Banaszak, Roni Shouval, Sergio Giralt, Gregory Goldgof, Jodi Mones, Jeffrey Zwicker, Rekha Parameswaran, Avi Leader, Cy R. Wilkins, Simon Mantha, Jeffrey Cohen, Jessica Durkee-Shock, Matthew Sedlock, Bita Shakoory, Irini Sereti, Miguel-Angel Perales, Gilles Salles, Santosha Vardhana, Joseph Oved, Steven Horwitz

Blood (2025) 146 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2025-2996

Published: 2025

Journal Articles

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 7090.

https://doi.org/10.1182/blood-2025-7090

Published: 2025

Journal Articles

Second primary malignancies in multiple myeloma: Incidence, survival and prognostic factors from a large single-center observational study

Blood (2025) 146 (Supplement 1): 2213.

https://doi.org/10.1182/blood-2025-2213

Published: 2025

Journal Articles

Low dose tocilizumab for mitigation of cytokine release syndrome with bispecific antibodies in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2210.

https://doi.org/10.1182/blood-2025-2210

Published: 2025

Journal Articles

Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study

Alexandra Gomez-Arteaga, Rory Shallis, Mariam Nawas, Landi Guo, Temitope Oloyede, Kwang Woo Ahn, Veronika Bachanova, Michael Byrne, Sergio Giralt, Lohith Gowda, Ann Jakubowski, Mark Litzow, Filippo Milano, Kristin Page, Wael Saber, Nelli Bejanyan, Larisa Broglie, Xinjie Xu, Jean Yared

Blood (2025) 146 (Supplement 1): 1060.

https://doi.org/10.1182/blood-2025-1060

Published: 2025

Journal Articles

Factors associated with remote healthcare utilization in MM patients undergoing autologous stem cell transplantation

Blood (2025) 146 (Supplement 1): 2632.

https://doi.org/10.1182/blood-2025-2632

Published: 2025

Journal Articles

Limitations of the IWG-MRT/ELN response criteria in defining post-transplant remission and clinical success in patients with myelofibrosis: A retrospective study

Charlotte Hughes, Brian Shaffer, Sergio Giralt, Esperanza Papadopoulos, Ann Jakubowski, Doris Ponce, Boglarka Gyurkocza, Miguel-Angel Perales, Roni Tamari

Blood (2025) 146 (Supplement 1): 2506.

https://doi.org/10.1182/blood-2025-2506

Published: 2025

Journal Articles

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Blood (2025) 146 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2025-3723

Published: 2025

Journal Articles

Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial

Blood (2025) 146 (Supplement 1): 2273.

https://doi.org/10.1182/blood-2025-2273

Published: 2025

Journal Articles

Functionally high-risk disease is associated with inferior outcomes after chimeric antigen receptor T-cell therapy for relapsed refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2291.

https://doi.org/10.1182/blood-2025-2291

Published: 2025

Journal Articles

Lenalidomide-related diarrhea is associated with gut microbiota dysbiosis and disruption of the bile acid pool

Blood (2025) 146 (Supplement 1): 2233.

https://doi.org/10.1182/blood-2025-2233

Published: 2025

Journal Articles

Fludarabine pharmacokinetic model identifies an optimal exposure associated with improved outcomes in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide

Blood (2025) 146 (Supplement 1): 113.

https://doi.org/10.1182/blood-2025-113

Published: 2025

Journal Articles

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Blood (2025) 146 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2025-1033

Published: 2025

Journal Articles

Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 6296.

https://doi.org/10.1182/blood-2025-6296

Published: 2025

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4735.

https://doi.org/10.1182/blood-2024-201824

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Tumor mutational burden as a novel biomarker of resistance to CD19 CAR-T cell therapy in large B-cell lymphoma

Belantamab mafodotin, nirogacestat, and pomalidomide in patients with relapsed/refractory multiple myeloma

Phase II trial of maintenance therapy with iberdomide after autologous hematopoietic cell transplant for patients with multiple myeloma previously treated with lenalidomide

Effectiveness of remote patient monitoring in enabling outpatient step-up dosing for bispecifics at a large academic cancer center in the USA

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Second primary malignancies in multiple myeloma: Incidence, survival and prognostic factors from a large single-center observational study

Low dose tocilizumab for mitigation of cytokine release syndrome with bispecific antibodies in relapsed/refractory multiple myeloma

Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study

Factors associated with remote healthcare utilization in MM patients undergoing autologous stem cell transplantation

Limitations of the IWG-MRT/ELN response criteria in defining post-transplant remission and clinical success in patients with myelofibrosis: A retrospective study

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial

Functionally high-risk disease is associated with inferior outcomes after chimeric antigen receptor T-cell therapy for relapsed refractory multiple myeloma

Lenalidomide-related diarrhea is associated with gut microbiota dysbiosis and disruption of the bile acid pool

Fludarabine pharmacokinetic model identifies an optimal exposure associated with improved outcomes in allogeneic hematopoietic cell transplantation recipients receiving post-transplant cyclophosphamide

Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only